The antiproliferative activities of 12-oxoheteronemin and heteronemin were evaluated in six cancer cell lines and IC 50 values ranging from 0.66 to 1.35 M were obtained. In four of the cell lines, 12-oxoheteronemin and heteronemin were equipotent; however, in two estrogenic receptor-positive cell lines, heteronemin showed a stronger potency. Both compounds had no overt effects on cell cycle distribution in HeLa cells, but did rapidly initiate apoptosis as evidenced by increased sub-G 1 populations of cells and caspase-dependent PARP cleavage.
Heteronemin is a marine-derived scalarane sesterterpene found primarily in sponges of the genera Hyrtios [1] and Hyatella [2] . The compound was reported to show a wide range of biological properties, including cytotoxic [1b,c] and antimycobacterial activities [3] . Its antimycobacterial activity in the low M range prompted an extensive SAR study, and QSAR models have been proposed [4] . Among the profiled scalaranes, 12-oxoheteronemin was the most potent (MIC against M. tuberculosis H37Ra, 0.23 M) [4a] . Interestingly, whereas heteronemin and 12-oxoheteronemin were indiscriminating both in the antimycobacterial and cytotoxic activities, several other scalaranes were more selective [4] , hence suggesting the possibility of scalaranes with better selectivity. Here, the cellular effects of 12-oxoheteronemin were probed and compared with heteronemin, using cancer cells as cellular settings. This study could allow the identification of key pathways implicated in the effects in diverse organisms, and facilitate SAR directed at these activities of the scalaranes.
12-Oxoheteronemin and heteronemin were examined for their antiproliferative activity targeting six cancer cell lines, i.e., HeLa, PC3, MDA-MB-231, Hs578T, MCF-7, and T47D, using SRB assay [5] . Both compounds were active against all six cell lines with IC 50 s in the range 0.6-1.3 M (Table 1) . Noticeably, with HeLa, PC3, MDA-MB-231, and Hs578T cells, heteronemin and 12-oxoheteronemin were comparably potent (IC 50 s 0.6-0.8 M). However, 12-oxoheteronemin was slightly less sensitive to the estrogen receptor positive MCF-7 and T47D breast cancer cells by factors of 1.6-1.8 compared with its effects against the other four cell lines, and to the potency of heteronemin against the same cell lines. On the other hand, MDA-MB-231 and Hs578T cells, the breast cancer cell lines that are devoid of estrogen and progesterone receptors, were equally sensitive towards both compounds. These results indicate the possibility that the different effects of 12-oxoheteronemin and heteronemin on certain cell types may relate to hormone receptors. Due to the technical difficulties in the responsiveness and consistency of culture maintenance, the HeLa cell line was chosen for the extended experiments. The effects of heteronemin and 12-oxoheteronemin on cell cycles were examined at 2.5 and 5 M. Cell cycle histograms showed only minor effects (Figure 1) , with no cellular accumulation at any phases of the cell cycle after 18 h as compared with the negative control ( Figure 1a ). However, a dose dependent increase in the sub-G 1 peak, indicative of cell death, was observed with each compound.
Heteronemin has been proposed to initiate apoptosis [6] ; nonetheless, such an effect has never been reported with other analogs, i.e., 12-oxoheteronemin. The apoptosis inducing property was examined through poly(ADP-ribose) polymerase (PARP) cleavage.
Whereas tracing the caspase cascade is a more conventional approach, tracking PARP cleavage, which is one of the final results of caspases-3 and -7, has been proposed to be an adequate assay for apoptosis [7] . Here, a time-and dose-dependent expression of cleaved PARP (Figure 2 ) was observed. PARP cleavage was apparent at 12 h after treatment with 2.5 M of either heteronemin or 12-oxoheteronemin, and as early as at 8 h with a 5 M concentration. This is a rapid onset of apoptosis since the positive control paclitaxel, at ten times its IC 50 , initiated PARP cleavage beginning after 18 h of exposure. This is the first observation of rapid-onset apoptosis induced by the antiproliferative scalaranes.
Although unable to be accounted for, it should be mentioned here that there were discrepancies between the published results and ours.
Heteronemin was reported to inhibit trypsin and chymotrypsin, implying proteasome inhibition [6] . However, when determining ubiquitinated protein accumulation, none such proteins were detected upon treatment of HeLa cells with either compound at 5 M (data not shown). This may result from the early apoptotic response discussed above and, therefore, either confounding the enzyme activities or preventing the accumulation of the ubiquitinated proteins. Comparative studies targeting different cell types, particularly focusing on hormone-sensitive and -insensitive cell lines, as well as a parallel study with multiple time points, need to be conducted.
Experimental
Materials: Heteronemin and 12-oxoheteronemin were obtained as reported previously [4a] , and were subjected to the investigation without additional purification.
Cell cultures:
HeLa cervical cancer cells were maintained in basal Eagle's medium and PC3 prostate cancer cells in RPMI1640 medium, both supplemented with 10% FBS and 50 mg/mL gentamicin. All four breast adenocarcinoma cell lines (Hs578T, MDA-MB-231, MCF-7, and T47D) were cultured in modified IMEM with 10% FBS and 25 mg/mL gentamicin. All cells were maintained in a humidified CO 2 incubator (37C, 5% CO 2 , 95% RH). All cell lines were sub-cultured every 2-3 days and were tested during their logarithmic phase of growth.
Antiproliferative activity: The antiproliferative activity was determined using a SRB colorimetric assay [5] . The IC 50 s were calculated from the linear regression from the dose-response plot, and were expressed as a mean valueSD. Camptothecin was used as a reference standard (IC 50 0.670.03 M against HeLa cells).
Flow cytometry:
HeLa cells were cultured as described, and were exposed to the test samples at 2.5 and 5.0 M for 18 h, at which time the cells were harvested and treated with Krishan's reagent for DNA staining. Cell cycle analyses were performed on a Becton FACScan flow cytometer.
Western blotting: HeLa cells were also chosen for assessment of apoptosis induction. After a 24 h exposure period, cells were harvested and solubilized with the cell extraction buffer (Invitrogen), then mixed with protease inhibitor cocktails. The amount of proteins was measured using Coomassie Blue colorimetric assay, and referred to BSA as standard protein. Cell lysates were fractionated using SDS-PAGE, followed by a PVDF membrane. Targeted proteins were probed with PARP p85 primary antibody (anti-PARP p85 fragment, Promega), and visualized using horseradish peroxidase-conjugated secondary antibody, with Western lighting TM ECL-plus reagent for chemiluminescent detection (Perkin Elmer). Paclitaxel and bartezomib were used as positive standards. Actin was used as a reference, and detected with anti-actin antibody produced in rabbit (Sigma-Aldrich).
